GENE ONLINE|News &
Opinion
Blog

2018-03-06|

6 March, 2014: First time Scientist gene-editing Immune Cells Successful, open a new treatment possibility for AIDS

by GeneOnline
Share To

A research team from the Perelman School of Medicine, University of Pennsylvania, enrolled 12 patients in an uncontrolled study of a single dose of ZFN-modified autologous CD4 T cells. The patients had the chronic aviremic HIV infection while they were receiving highly active antiretroviral therapy. After the infusion of 10 billion autologous CD4 T cells, the blood level of HIV DNA decreased in most patients. This study was a milestone for gene-editing technology application on fatal disease treatment.

Reference
http://www.nejm.org/doi/full/10.1056/NEJMoa1300662

Image Source
https://en.wikipedia.org/wiki/HIV

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Looking Back at the Cell and Gene Therapy Leaders That Made Waves in 2024
2025-03-31
End of USAID Support in Kenya Raises Concerns Over Health Care and Livelihoods
2025-03-16
Study Uncovers Persistent Health Risks in HIV Patients Despite Effective Treatment
2025-03-01
LATEST
Comparative Analysis of Tirzepatide (Zepbound/Mounjaro) and Semaglutide (Wegovy) for Weight Loss
2025-05-12
Donald Trump’s “Most Favored Nation” Executive Order on Drug Pricing
2025-05-12
Discover Investment Opportunities & Innovation at International Healthcare Week in Hong Kong from May
2025-05-12
The Buffett Paradox: Cola, Happiness, and a Biotech Longevity Enigma
2025-05-11
President to Sign Executive Order on Trade Enforcement Monday Morning
2025-05-11
Trump to Sign Executive Order Linking U.S. Drug Prices to International Levels.
2025-05-11
Podcast Highlights Agile Biopharmaceutical Firms’ Strategies for Navigating Complex Clinical Trials
2025-05-11
EVENT
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top